Avalo Therapeutics's total assets for Q2 2026 were $490.78M, an increase of 391.35% from the previous quarter. DE:C6K0 total liabilities were $42.12M for the fiscal quarter, a 33.45% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.